Pharmaceutical Technology
DECEMBER 19, 2022
This economic change impacts employment, income, industrial production, and more, and the pharmaceutical industry will not be exempt. by the end of 2023 and may continue to rise in 2024 to 5%. Companies relying on angel investors and venture capitalists will be most affected by an economic downturn.
Pharmaceutical Technology
JANUARY 16, 2023
This could evolve into pharmaceutical companies dealing with semi-permanent higher input costs and other interlinked challenges for longer than current baseline predictions. The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles. Free Report.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JANUARY 16, 2023
This could evolve into pharmaceutical companies dealing with semi-permanent higher input costs and other interlinked challenges for longer than current baseline predictions. The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles. Free Report.
Pharmaceutical Technology
FEBRUARY 17, 2023
However, Amgen and other pharmaceutical companies have been criticised when they opted to choose the drug’s dosage based on the MTD model, which is commonly used in dose-finding trials. In 2021, Amgen agreed to conduct a Phase II study (NCT04933695), which is supposed to complete in May 2024, according to Clinicaltrials.gov.
Pharmaceutical Technology
MAY 5, 2023
To keep within this limit, pharmaceutical companies have had to pay rebates on their sales back to the NHS on all expenditures above the capped limit. Companies that choose not to take part in the voluntary scheme must partake in a statutory scheme. The revised voluntary scheme has an expected launch on January 1, 2024.
pharmaphorum
APRIL 19, 2022
I think the most important thing is making a good team and also good communication within that team is very important. Next in the pipeline, is a non-opioid treatment for chronic pain looking to complete pre-clinical studies by 2024. Everyone in our team is very valuable,” he said. “I Moving to the global stage.
Pharmaceutical Technology
JUNE 15, 2023
Generic and biosimilar pharmaceutical company and Novartis subsidiary Sandoz announced its plan to accelerate patient access to biosimilars. By the end of the year, the company will seek to identify similar issues in European biosimilars, followed by the Middle East and Africa in Q1 2024, and Asia Pacific in Q2.
Expert insights. Personalized for you.
69 
Let's personalize your content